Literature DB >> 7897129

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade.

S A Hall1, C G Cigarroa, L Marcoux, R C Risser, P A Grayburn, E J Eichhorn.   

Abstract

OBJECTIVES: We examined the time course of ventricular functional improvement in patients with dilated cardiomyopathy who received beta-blockade and the long-term effects of beta-blockade on ventricular mass and geometry in these patients.
BACKGROUND: Previous studies have shown that beta-adrenergic blocking agents when administered long term improve ventricular function in patients with heart failure. However, the time course of improvement in ventricular function and the long-term effects of beta-blockade on ventricular mass and geometry are not known.
METHODS: Twenty-six men with dilated cardiomyopathy underwent serial echocardiography on days 0 and 1 and months 1 and 3 of either metoprolol (n = 16) or standard therapy (n = 10). At 3 months all patients on standard therapy were crossed over to metoprolol, and late echocardiograms were obtained after 18 +/- 5 (mean +/- SD) months of metoprolol therapy. All echocardiograms were read in blinded manner.
RESULTS: Patients treated with metoprolol had an initial decline (day 1 vs. day 0) in ventricular function (increase in end-systolic volume and decrease in ejection fraction). Ventricular function improved between months 1 and 3 (p = 0.013, metoprolol vs. standard therapy). Left ventricular mass regressed at 18 months (333 +/- 85 to 275 +/- 53 g, p = 0.011) but not at 3 months. Left ventricular shape became less spherical and assumed a more normal elliptical shape by 18 months (major/minor axis ratio 1.5 +/- 0.2 to 1.7 +/- 0.2, p = 0.0001).
CONCLUSIONS: Patients with heart failure treated with metoprolol do not demonstrate an improvement in systolic performance until after 1 month of therapy and may have a mild reduction in function initially. Long-term therapy with metoprolol results in a reversal of maladaptive remodeling with reduction in left ventricular volumes, regression of left ventricular mass and improved ventricular geometry by 18 months.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7897129     DOI: 10.1016/0735-1097(94)00543-y

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  94 in total

Review 1.  Heart Failure: Treatment strategies for heart failure: beta blockers andantiarrhythmics.

Authors:  A P Maggioni
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

Review 2.  Clinical case studies in heart failure management.

Authors:  R J MacFadyen; P Shiels; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

3.  Facts and principles learned at the 31st Annual Williamsburg Conference on Heart Disease.

Authors:  Mark A Peterman; Hassan Farooq; William C Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-04

Review 4.  Initiation and use of beta-blockers in class IV heart failure.

Authors:  Feras M Bader; John F MacGregor; Edward M Gilbert
Journal:  Curr Heart Fail Rep       Date:  2004-07

Review 5.  Dobutamine stress echocardiography: does it predict response to beta-blockers in patients with heart failure?

Authors:  Sripal Bangalore; Khashayar Hematpour; Farooq A Chaudhry
Journal:  Curr Heart Fail Rep       Date:  2006-06

Review 6.  Beta-blocker use in decompensated heart failure.

Authors:  Rami Alharethi; Ray E Hershberger
Journal:  Curr Heart Fail Rep       Date:  2006-06

7.  Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model.

Authors:  Long P Nguyen; Rui Lin; Sergio Parra; Ozozoma Omoluabi; Nicola A Hanania; Michael J Tuvim; Brian J Knoll; Burton F Dickey; Richard A Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

Review 8.  Drugs for cardiovascular risk reduction in the diabetic patient.

Authors:  D S Bell
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

Review 9.  Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances.

Authors:  Kelley P Anderson
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

10.  β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation.

Authors:  Mohsin Khan; Sadia Mohsin; Daniele Avitabile; Sailay Siddiqi; Jonathan Nguyen; Kathleen Wallach; Pearl Quijada; Michael McGregor; Natalie Gude; Roberto Alvarez; Douglas G Tilley; Walter J Koch; Mark A Sussman
Journal:  Circ Res       Date:  2012-12-14       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.